163 related articles for article (PubMed ID: 30473779)
1. Burden of cytomegalovirus reactivation post kidney transplant with antithymocyte globulin use in Thailand: A retrospective cohort study.
Chitasombat MN; Watcharananan SP
F1000Res; 2018; 7():1568. PubMed ID: 30473779
[No Abstract] [Full Text] [Related]
2. Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin.
Jewani PK; Pouch SM; Kissling KT
Clin Transplant; 2018 Nov; 32(11):e13420. PubMed ID: 30290013
[TBL] [Abstract][Full Text] [Related]
3. The Influence of Antithymocyte Globulin Dose on the Incidence of CMV Infection in High-risk Kidney Transplant Recipients Without Pharmacological Prophylaxis.
de Paula MI; Bae S; Shaffer AA; Garonzik-Wang J; Felipe CR; Cristelli MP; Waldram MM; Massie AB; Medina-Pestana J; Segev DL; Tedesco-Silva H
Transplantation; 2020 Oct; 104(10):2139-2147. PubMed ID: 31978003
[TBL] [Abstract][Full Text] [Related]
4. The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors.
Busca A; Passera R; Pini M; Zallio F; Dellacasa C; Audisio E; Giaccone L; Maffini E; Costa C; Cavallo R; Bruno B
Am J Hematol; 2015 Jun; 90(6):E117-21. PubMed ID: 25752810
[TBL] [Abstract][Full Text] [Related]
5. Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction.
Couzi L; Helou S; Bachelet T; Martin S; Moreau K; Morel D; Lafon ME; Garrigue I; Merville P
Transplant Proc; 2012 Nov; 44(9):2809-13. PubMed ID: 23146529
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus in renal transplant recipients from living donors with and without valganciclovir prophylaxis and with immunosuppression based on anti-thymocyte globulin or basiliximab.
Andrade-Sierra J; Heredia-Pimentel A; Rojas-Campos E; Ramírez Flores D; Cerrillos-Gutierrez JI; Miranda-Díaz AG; Evangelista-Carrillo LA; Martínez-Martínez P; Jalomo-Martínez B; Gonzalez-Espinoza E; Gómez-Navarro B; Medina-Pérez M; Nieves-Hernández JJ
Int J Infect Dis; 2021 Jun; 107():18-24. PubMed ID: 33862205
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors of Cytomegalovirus Disease in Kidney Transplant Recipients: A Single-Center Study in Thailand.
Chiasakul T; Townamchai N; Jutivorakool K; Chancharoenthana W; Thongprayoon C; Watanatorn S; Avihingsanon Y; Praditpornsilpa K; Srisawat N
Transplant Proc; 2015 Oct; 47(8):2460-4. PubMed ID: 26518951
[TBL] [Abstract][Full Text] [Related]
8. Immunoguided Discontinuation of Prophylaxis for Cytomegalovirus Disease in Kidney Transplant Recipients Treated With Antithymocyte Globulin: A Randomized Clinical Trial.
Páez-Vega A; Gutiérrez-Gutiérrez B; Agüera ML; Facundo C; Redondo-Pachón D; Suñer M; López-Oliva MO; Yuste JR; Montejo M; Galeano-Álvarez C; Ruiz-San Millan JC; Los-Arcos I; Hernández D; Fernández-Ruiz M; Muñoz P; Valle-Arroyo J; Cano A; Rodríguez-Benot A; Crespo M; Rodelo-Haad C; Lobo-Acosta MA; Garrido-Gracia JC; Vidal E; Guirado L; Cantisán S; Torre-Cisneros J;
Clin Infect Dis; 2022 Mar; 74(5):757-765. PubMed ID: 34228099
[TBL] [Abstract][Full Text] [Related]
9. Selection of More Vulnerable Patients for Cytomegalovirus Infection in Renal Transplant Recipients With Antithymocyte Globulin Induction Therapy: An Analysis of Risk Factors and Cell-Mediated Immunity.
Jun KW; Lim JH; Hwang JK; Park SC; Kim JI; Yun SS; Kim MH
Transplant Proc; 2021 Sep; 53(7):2252-2260. PubMed ID: 34452738
[TBL] [Abstract][Full Text] [Related]
10. A split strategy to prevent cytomegalovirus after kidney transplantation using prophylaxis in serological high-risk patients and a pre-emptive strategy in intermediate-risk patients: Combining the best of two options?
Hellemans R; Wijtvliet V; Bergs K; Philipse E; Vleut R; Massart A; Couttenye MM; Matheeussen V; Abramowicz D
Transpl Infect Dis; 2021 Apr; 23(2):e13467. PubMed ID: 32935909
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.
Gabardi S; Magee CC; Baroletti SA; Powelson JA; Cina JL; Chandraker AK
Pharmacotherapy; 2004 Oct; 24(10):1323-30. PubMed ID: 15628830
[TBL] [Abstract][Full Text] [Related]
12. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
[TBL] [Abstract][Full Text] [Related]
13. Low-dose valganciclovir prohylaxis is efficacious and safe in cytomegalovirus seropositive heart transplant recipients with anti-thymocyte globulin.
Eriksson M; Jokinen JJ; Söderlund S; Hämmäinen P; Lommi J; Lemström K
Transpl Infect Dis; 2018 Jun; 20(3):e12868. PubMed ID: 29512249
[TBL] [Abstract][Full Text] [Related]
14. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.
Huurman VA; Kalpoe JS; van de Linde P; Vaessen N; Ringers J; Kroes AC; Roep BO; De Fijter JW
Diabetes Care; 2006 Apr; 29(4):842-7. PubMed ID: 16567825
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of valacyclovir prophylaxis for cytomegalovirus infection after anti-thymocyte globulin as rejection therapy.
Ko EJ; Yu JH; Yang CW; Chung BH
Korean J Intern Med; 2019 Mar; 34(2):375-382. PubMed ID: 29237252
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
Reusing JO; Feitosa EB; Agena F; Pierrotti LC; Azevedo LSF; Kotton CN; David-Neto E
Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy.
Felipe C; Ferreira AN; de Paula M; Viana L; Cristelli M; Medina Pestana J; Tedesco-Silva H
Transpl Infect Dis; 2019 Dec; 21(6):e13106. PubMed ID: 31081566
[TBL] [Abstract][Full Text] [Related]
18. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
19. Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.
Cristelli MP; Felipe CR; Prizmic PSS; de Azevedo VFD; Viana LA; Tavares MG; Wagner de Castro Lima Santos D; de Paula MI; Medina-Pestana JO; Tedesco-Silva Junior H
Clin Transplant; 2019 Oct; 33(10):e13689. PubMed ID: 31400155
[TBL] [Abstract][Full Text] [Related]
20. Age matters: older age as a risk factor for CMV reactivation in the CMV serostatus-positive kidney transplant recipient.
Hemmersbach-Miller M; Alexander BD; Pieper CF; Schmader KE
Eur J Clin Microbiol Infect Dis; 2020 Mar; 39(3):455-463. PubMed ID: 31758441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
